Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL896278 | 1.00 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL15542352 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL27663119 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL9767768 | 0.98 | GSR (0.59) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL12470732 | 0.96 | GSR (0.57) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL25283016 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL3427044 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL1281705 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL5691753 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL1034337 | 0.95 | GSR (0.61) | GSRRNPEPGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 916 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118986781-B | Composition for improving mitochondrial activity and application of composition in cosmetics | 山东福瑞达生物股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-3612542-B1 | ENERGY-EFFICIENT SOLVENT-FREE METHOD FOR PRODUCING METAL CHELATES | TECHNISCHE UNIV CLAUSTHAL (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | claimed |
| US-12398157-B2 | Energy-efficient solvent-free method for producing metal chelates | TECHNISCHE UNIVERSITAT CLAUSTHAL (DE) | 2025-08-26 | — | — | US | claimed |
| CN-119896287-A | Feed for relieving transportation stress of lambs and preparation method thereof | 山东美事达农牧科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119481078-A | Transfer welding method of composite current collector | 江阴纳力新材料科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2025029611-A1 | THERAPIES FOR DISEASES OF COPPER METABOLISM | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2025-02-06 | — | — | WO | claimed |
| CN-105579048-B | Resin biocide composition comprising one or more resins selected from MF, UF, PF, MUF and phenolic resins and one or more soluble copper salts | L·A·艾姆斯蒂卡萨拉查 | 2024-11-26 | — | — | CN | claimed |
| CN-118986781-A | Composition for improving mitochondrial activity and application of composition in cosmetics | 山东福瑞达生物股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| CN-118975950-A | Skin care composition for improving skin reddening and drying problems and application thereof | 山东福瑞达生物股份有限公司 | 2024-11-19 | — | — | CN | claimed |
| WO-2006138609-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | DYNAMIS THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| CN-1836542-A | Novel feedstuff matched with safe aquatic product | MIU SHUHUA (CN) | 2006-09-27 | — | — | CN | claimed |
| CN-1824606-A | Controlled release type copper supplementing and its preparing method and use | UNIV ZHEJIANG (CN) | 2006-08-30 | — | — | CN | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| WO-2004100896-A2 | ANTI-AGING NUTRITIONAL SUPPLEMENT | GIAMPAPA VINCENT C (US) | 2004-11-25 | — | — | WO | claimed |
| CN-1532191-A | Process for producing Ne-teriary butoxy carbonyl lysine | 四川三高生化股份有限公司 | 2004-09-29 | — | — | CN | claimed |
| US-20040105894-A1 | Trace Metals synergized copper nucleotides and copper glycosides for anti-aging and antiviral compositions | GUPTA SHYAM K (US) | 2004-06-03 | — | — | US | claimed |
| US-20040001817-A1 | Anti-aging nutritional supplement | KRONOGEN SCIENCES INC. | 2004-01-01 | — | — | US | claimed |
| US-6447809-B1 | MIXTURES OF MICROCRYSTALLINE HYDROXYAPATITE, CHOLECALCIFEROL AND IPRIFLAVONE ADMINISTERED AS OSTEOBLASTS STIMULANTS FOR PREVENTION OF OSTEOPOROSIS | METAGENICS, INC. | 2002-09-10 | — | — | US | claimed |
| EP-0725057-B1 | Alkylsulfonyl or alkylaminocarbonyl substituted lysine derivatives, process for their preparation, their use especially in cosmetics and compositions containing them | OREAL (FR) | 1997-01-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | GSR 2602/4885RNPEP 620/4885GNAI3 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.